Osteoporosis

The FDA has recently announced the approval of Zurzuvae, the first and only oral, once-daily treatment for postpartum depression. Prior to the approval, medication for postpartum depression was only available through IV injection.

SANTA FE, N.M. — In this video exclusive, Michael R. McClung, MD, discusses strategies for drug holidays and transitions between osteoporosis therapies.

SANTA FE, NEW MEXICO — In this video exclusive, Christopher Kovacs, MD, FRCP, FACP, FACE, talks about osteoporosis and fragility fractures associated with pregnancy and lactation.

SANTA FE, N.M. — In this video exclusive, E. Michael Lewiecki, MD, FACE, FACP, describes Bone Health ECHO, a virtual community of physicians who review osteoporosis and bone-disease cases together each week via video conferencing.

SANTA FE, N.M. — In this video exclusive, Jacques P. Brown, MD, discusses clinical applications of bone turnover markers in managing osteoporosis.

Despite the high prevalence of osteoporosis among postmenopausal women in urban Tianjin, China, most women had no knowledge of the dangers or the importance of early diagnosis and treatment, according to findings published in Menopause.

Older men who have a rapid decline in cortical bone over 4 years have a higher risk for sustaining a future fracture, according to findings published in The Journal of Bone and Mineral Research.

CHICAGO — An oral robotic pill may provide an alternative delivery method to subcutaneous injection for teriparatide and other biologics, according to a speaker at ENDO 2023.

Among postmenopausal women, hormone preparations increased lumbar spine bone mineral density and had a protective effect against osteopenia, according to a real-world study published in Menopause.

Published results showed biomechanical CT analysis may identify patients aged 50 years or older with primary spinal fusion and osteoporosis who had elevated risks for reoperation and vertebral fracture.